KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Macitentan Plus Tadalafil Single-Tablet Combination Therapy in Chinese Patients With Pulmonary Arterial Hypertension: A Subgroup Analysis of the A DUE Study.

Fenling Fan, Luying Sun, Zhenwen Yang, Lan Wang, Qiguang Wang, Jiang Li, Hong Gu, Weiping Xie, Nuofu Zhang, Jia Bin, Hany Rofael, Michael Friberg, Jakob A Hauser

Pulm Circ 15(4) e70194

PMID41250682
PMCIDPMC12619956
DOI10.1002/pul2.70194
发表日期2025-11-18
摘要

摘要

Macitentan 10 mg and tadalafil 40 mg single-tablet combination therapy (M/T STCT) has been evaluated in the global A DUE study (NCT03904693). Here, we report the results of a subgroup analysis in participants from China. This double-blind, active-controlled, Phase 3 A DUE study randomized patients with symptomatic pulmonary arterial hypertension (PAH) to receive M/T STCT, macitentan, or tadalafil depending on their baseline PAH treatment (treatment-naïve, endothelin receptor antagonist, or phosphodiesterase Type 5 inhibitor monotherapy). The primary end point was change in pulmonary vascular resistance (PVR) expressed as the ratio of geometric means (GMR) of Week 16 to baseline. A total of 187 patients were randomized, including 23 patients in China. PVR reduction was significantly greater with M/T STCT compared with macitentan (50%) and tadalafil (41%) (adjusted GMRs were 0.50; 95% confidence level [CL]: 0.35-0.72; p = 0.0017 and 0.59; 95% CL: 0.43-0.80; p = 0.0040, respectively) in Chinese patients. M/T STCT was well tolerated in Chinese patients; the safety profile was consistent with that of macitentan and tadalafil monotherapies, and that of the overall population. In conclusion, in Chinese patients with PAH, PVR was reduced with M/T STCT versus either monotherapy after 16 weeks of treatment; the safety profile of M/T STCT was in line with the known safety profile of the individual components and appeared consistent with the overall population, although data should be interpreted with caution due to the small sample size. Our findings support the use of M/T STCT for PAH in China. Trial registration: ClinicalTrials.gov https://clinicaltrials.gov/ NCT03904693 (April 5, 2019).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。